Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mark Pruzanski
AddedMar 31, 2024
UpdatedMay 31, 2026
Mark Pruzanski

Mark Pruzanski

Board Member, Equillium

CrunchbaseLinkedIn

Mark Pruzanski's Career

Equillium
Equillium

Los Angeles, CA, US

Board Member· Board
Intercept Pharmaceuticals
Intercept Pharmaceuticals

New York City, NY, US

Board Member· Board
Tigris Pharmaceuticals
Tigris Pharmaceuticals

Bonita Springs, FL, US

Founder
Apple Tree Partners
Apple Tree Partners

New York City, NY, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mark Pruzanski's Career

Equillium
Equillium
Public$85M452017Los Angeles, CA, US
Board Member· Board

Leadership at Equillium

Martha J. DemskiMartha J. DemskiBoard Member
Bala ManianBala ManianBoard Member
Charlie McDermottCharlie McDermottBoard Member
Y. Katherine XuY. Katherine XuBoard Member
Bruce SteelBruce SteelBoard Member

Similar to Equillium

Q32 BioQ32 BioWaltham, MA, USBiotherapeuticsest. 2017Q32 BioWaltham, MA, US · est. 2017

Q32 Bio is a biotech firm developing therapies to balance the immune system in severe autoimmune diseases.

Series B · $106M44
HI-BioHI-BioSan Francisco, CA, USBiotechest. 2021HI-BioSan Francisco, CA, US · est. 2021

HI-Bio pioneers precision medicine, targeting cellular drivers to treat immune-mediated diseases.

Series B · $215M48
Thelium TherapeuticsThelium TherapeuticsSan Carlos, CA, USTherapeuticsest. 2019Thelium TherapeuticsSan Carlos, CA, US · est. 2019

Thelium Therapeutics: A preclinical firm in California, innovating agents for inflammatory diseases.

Series B · $18M1
Kezar Life SciencesKezar Life SciencesSouth San Francisco, CA, USMedicines, Therapeuticsest. 2015Kezar Life SciencesSouth San Francisco, CA, US · est. 2015

Kezar Life Sciences, a biotech firm, develops molecular therapeutics for autoimmune disorders in California.

Public · $123M84
Intercept Pharmaceuticals
Intercept Pharmaceuticals
Public$970M3412002New York City, NY, US
Board Member· Board

Leadership at Intercept Pharmaceuticals

Paolo FundaròPaolo FundaròBoard Member
Gino SantiniGino SantiniBoard Member
Dan BradburyDan BradburyBoard Member
Luca BenattiLuca BenattiBoard Member
Jerome DursoJerome DursoCEO

Similar to Intercept Pharmaceuticals

Mirum PharmaceuticalsMirum PharmaceuticalsFoster City, CA, USPharmaceuticalsest. 2018Mirum PharmaceuticalsFoster City, CA, US · est. 2018

Mirum Pharmaceuticals, Inc.: A US-based biopharmaceutical company specializing in cholestatic liver disease therapies.

Public · $497M196
Gilead SciencesGilead SciencesFoster City, CA, USPharmaceuticals, Therapiesest. 1987Gilead SciencesFoster City, CA, US · est. 1987

Gilead Sciences: An American biopharmaceutical firm innovating therapies for critical diseases.

Public · $2B17k
PTC TherapeuticsPTC TherapeuticsSouth Plainfield, NJ, USPharmaceuticalsest. 1998PTC TherapeuticsSouth Plainfield, NJ, US · est. 1998

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.

Public · $1.6B1.4k
Bristol Myers SquibbBristol Myers SquibbNew York City, NY, USPharmaceuticalsest. 1887Bristol Myers SquibbNew York City, NY, US · est. 1887

Leading American pharmaceutical company specializing in research and development.

Public · $10.6B34.3k
Tigris Pharmaceuticals
Tigris Pharmaceuticals
Series C$32.5M62005Bonita Springs, FL, US
Founder
Apple Tree Partners
Apple Tree Partners
Investment FirmInvestment Firm$5M471999New York City, NY, US
Co-Founder

Leadership at Apple Tree Partners

Seth L. HarrisonSeth L. HarrisonCo-Founder

Similar to Apple Tree Partners

ATPATPAustin, TX, USest. 2014ATPAustin, TX, US · est. 2014

ATP-I: A technology venture fund enabling rapid growth and sustainable success for emerging tech firms.

Investment Firm9
Olive Tree CapitalOlive Tree CapitalBoston, MA, USest. 2016Olive Tree CapitalBoston, MA, US · est. 2016

OT Management, LLC: A specialized investment advisory firm focusing on diverse asset classes.

Investment Firm5
AirTree VenturesAirTree VenturesSurry Hills, New South Wales, AUest. 2014AirTree VenturesSurry Hills, New South Wales, AU · est. 2014

AirTree Ventures: A global venture capital firm specializing in software, finance, digital commerce, media, and marketing.

Investment Firm185
Atherton Venture PartnersAtherton Venture PartnersMenlo Park, CA, USest. 2010Atherton Venture PartnersMenlo Park, CA, US · est. 2010

Atherton Venture Partners: A US-based venture capital firm investing in healthcare, life science, and IT sectors.

Investment Firm5

Mark Pruzanski's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Mark Pruzanski

Marc GitzingerMarc GitzingerCo-Founder · Venture KickAurelien GuichardAurelien GuichardCo-Founder · VersdNick SpringNick SpringFounder · BioVerasJohn SantiniJohn SantiniBoard Member · On Demand TherapeuticsChristopher M. CashmanChristopher M. CashmanBoard Member · University City Science CenterYushan YanYushan YanBoard Member · University of Delaware